Kyntra Bio (KYNB) Cost of Revenue (2019 - 2026)

Kyntra Bio has reported Cost of Revenue for 8 years, with the latest figure at $4.1 million in Q1 2026.

• Quarterly Cost of Revenue rose 1529.37% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (up 184.16% YoY) and the FY2025 annual result came in at $556000.0, down 96.43% from the prior year.
• Cost of Revenue rose to $4.1 million in Q1 2026 per KYNB's latest filing, from $278000.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $21.1 million in Q1 2024 and troughed at -$9.5 million in Q4 2023.
• A 5-year average of $2.6 million and a median of $3.5 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2026: Cost of Revenue sank 292.47% in 2023, then jumped 1529.37% in 2026.
• Over 5 years, Cost of Revenue stood at $4.9 million in 2022, then tumbled by 292.47% to -$9.5 million in 2023, then jumped by 38.33% to -$5.8 million in 2024, then jumped by 104.76% to $278000.0 in 2025, then jumped by 1376.98% to $4.1 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $4.1 million, $278000.0, and $58000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.